CHPA’s Health In Hand Foundation holds 10th Anniversary Gala
Over 350 industry leaders from 100 companies gathered at The Bellevue Hotel for this milestone event and a major fundraiser for the Foundation’s consumer education initiatives.
CHPA
Proposed acetaminophen warning conflicts with FDA’s standard that OTC labels be “Clear and Truthful”
Discouraging acetaminophen use when taken as directed by a health professional could push pregnant patients toward NSAIDs or no treatment, both of which can adversely affect pregnancy outcomes.
CHPA disputes autism claims and defends acetaminophen safety
Decades of use, FDA safety reviews, and leading medical groups confirm the safety of acetaminophen when used as directed.
CHPA releases statement on APAP use during pregnancy
“Current research has not established a causal link between acetaminophen use and adverse neurodevelopmental outcomes.”
CHPA’s Health In Hand Foundation announces 2025 U.S. Self-Care Marketing Awards finalists
This year’s competition had the highest participation rate since its inception in 2019, with a 32% increase in submissions over 2024.
CHPA’s Health In Hand Foundation launches national back-to-school health campaigns
Backed by CHPA member companies Kenvue and Colgate-Palmolive, and developed in collaboration with The Skin Cancer Foundation and the American Dental Association (ADA), the programs will reach more than 1.2 million students nationwide during the back-to-school season.
FDA Center heads to take the stage together at CHPA Regulatory Conference
Each year, CHPA’s RSQ Conference unites industry, regulators, and academia to focus on the evolving self-care sector.
Illinois expands consumer access to PSE and strengthens support for the system that prevents diversion
"The passage of HB 3087 represents a significant victory for both consumer access and public safety,” said Carlos Gutierrez, vice president of State & Local Government Affairs at CHPA.
CHPA applauds Senate HELP for advancing OMUFA with key wins for self-care; calls for GRAS/E Clarity
The legislation passed out of Committee today includes important provisions to accelerate the development and acceptance of innovative, non-animal testing methods for topically applied products, including sunscreens.
CHPA applauds Senate introduction of OMUFA
Industry calls for clear GRAS/E standards and broader adoption of non-animal testing to advance innovation and safety across all topical OTC products.
CHPA welcomes new board members at June meeting
“Each brings a wealth of leadership experience, strategic insight, and a deep commitment to consumer health and wellness.”
Bipartisan lawmakers relaunch dietary supplement caucus
The congressional caucus will host nonpartisan briefings on supplements, covering science, regulation, and their potential to cut healthcare costs and boost wellness.
CHPA applauds bipartisan SAFE Sunscreen Standards Act
The legislation recognizes sunscreen's vital role in skin cancer prevention and seeks to broaden effective sun protection options for U.S. consumers.
CHPA survey shows strong support for dietary supplement reform
While most consumers trust dietary supplements are safe, there is still room to strengthen further confidence in their safety and awareness of how they are regulated.
Dr. Scott Furness joins CHPA’s senior management team
Dr. Furness joins CHPA after over 25 years at the FDA, where he held several leadership positions.
CHPA submits official comments on Section 232 National Security Investigation of Pharmaceuticals
“These products deliver proven value—every $1 spent on OTC medicines saves over $7 in healthcare costs, totaling $167 billion in annual savings through avoided doctor visits and lower-cost treatment options."